It also showed plasma PSA reduction potency similar to that of the traditional AR antagonist, enzalutamide, but at lower doses, and demonstrated efficacy in enzalutamide-resistant PC xenograft models (78). This evidence concerns the gene AR and pachyonychia congenita.